https://www.livewiremarkets.com/wires/a-de-risked-biotech-with-4x-upside
In HASHAN DE SILVA's article, he said
the double-digit royalties on sales (which we believe are in the 10-15% range depending on the level of annual sales).
For calculation, he is using a blended 12.5% royalty rate and 50% market penetration. As a result, Neuren would receive ~A$100m per year on total Acadia sales of trofinetide of US$560m.
Ann: Investor Presentation, 24 February 2023, page-14
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.59 |
Change
0.380(2.50%) |
Mkt cap ! $1.992B | |||
| Open | High | Low | Value | Volume |
| $15.51 | $15.82 | $15.46 | $11.26M | 722.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 696 | $15.59 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.67 | 6942 | 8 |
View Market Depth
| Last trade - 16.10pm 30/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |